News Briefs

AIDS Drug Will Be Offered in Poor Countries at Cost

April 4, 2003

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Foster City, Calif.-based Gilead Sciences Inc. says it will begin offering its AIDS drug Viread at cost to 68 of the world's poorest countries. The drug maker will offer Viread to "qualified" nations throughout Africa, as well as to 15 other poor countries, for $1.30 per once-daily pill, or $475 a year. A year's supply of Viread in the United States costs roughly $4,300. Gilead said the lower price covers only its cost of manufacturing the drug and overseeing distribution. While clinics that wish to receive Viread must be accredited AIDS care facilities, they will not have to work through local governments to participate. AIDS activists called the program a welcome step but noted that, like other AIDS drug access plans in developing countries, it still falls short of the steps necessary to ensure that million of AIDS patients receive the treatment they need.

Back to other CDC news for April 4, 2003

Previous Updates

Adapted from:
Wall Street Journal

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.